Evaluating temsirolimus activity in multiple tumors: a review of clinical trials.
about
Dietary interventions to extend life span and health span based on calorie restrictionMethyl 2-cyano-3,11-dioxo-18-olean-1,12-dien-30-oate (CDODA-Me), a derivative of glycyrrhetinic acid, functions as a potent angiogenesis inhibitor.Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation.Rapamycin inhibits anal carcinogenesis in two preclinical animal models.Sirolimus demonstrates activity in the primary therapy of acute graft-versus-host disease without systemic glucocorticoids.Targeting cap-dependent translation blocks converging survival signals by AKT and PIM kinases in lymphoma.Cardiotoxicity of molecularly targeted agentsPTPN11-associated mutations in the heart: has LEOPARD changed Its RASpots?Activation of lysosomal function in the course of autophagy via mTORC1 suppression and autophagosome-lysosome fusion.Pharmacotherapy of neuroblastoma.Development of target-specific treatments in multiple myeloma.Selecting multimodal therapy for rhabdomyosarcoma.Post-transplant malignancy: reducing the risk in kidney transplant recipients.Modulating autophagy: a strategy for cancer therapyIntranuclear function for protein phosphatase 2A: Pph21 and Pph22 are required for rapamycin-induced GATA factor binding to the DAL5 promoter in yeastThe therapeutic potential of mTOR inhibitors in breast cancer.Vascular tumors have increased p70 S6-kinase activation and are inhibited by topical rapamycin.Hypoxia regulates the sperm associated antigen 4 (SPAG4) via HIF, which is expressed in renal clear cell carcinoma and promotes migration and invasion in vitro.Widespread deregulation of phosphorylation-based signaling pathways in multiple myeloma cells: opportunities for therapeutic interventionExploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors.Phase II trial of temsirolimus alone and in combination with irinotecan for KRAS mutant metastatic colorectal cancer: outcome and results of KRAS mutational analysis in plasma.
P2860
Q24595003-E8D2972D-6BE2-4DC1-99E4-4873BA0AA266Q34214684-D14C0727-9241-4E86-845B-F3BB53B176DFQ34627120-A347177B-1DFC-4490-A00B-BC6A7CA2A2C1Q34679829-17F547B0-9792-47CF-AB4B-12E5E84C2775Q35193740-6FD26A4B-DAE6-4CD0-B509-F6BCFBDD620FQ35208375-685B8949-A09D-4849-8D02-ECEDCBABAF34Q35878459-FDDB7536-AD14-4938-87F5-1EBE05DC1B4AQ36025665-129B7872-3536-4039-9537-D87DB9B64D6EQ36739965-FAA2F954-4B86-4276-A394-E165FAB12CF0Q37735199-14E21D9A-B6D2-47E3-BCBF-7BF0FAE7F627Q37771370-81019792-053A-4EA7-8892-577E2E39A934Q37782096-61FB3975-DEBB-44F6-9145-6F9D6BC71C88Q37863680-1D188191-42FF-4B3F-BDAF-8E6C3F9E1431Q37940741-3C6B087F-8151-445F-AA22-4276BA5ECC17Q38339843-7229FBA4-C3E3-4C1B-8967-16A843ADB7D9Q38802412-D918FCB5-EF76-447C-844F-E856F4C7445BQ39111280-06B83067-BD3F-4E8B-BCA8-48D9C5E81C8DQ39131858-9C47335C-8765-47FF-889A-240F787FBC6CQ39548450-047395AE-A1E3-4511-A281-615B68A669D0Q39676203-37302354-CC5B-4AD4-B344-571126A89D25Q45782126-AA5F6C48-A92F-4DFC-85B0-68A935709954
P2860
Evaluating temsirolimus activity in multiple tumors: a review of clinical trials.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Evaluating temsirolimus activity in multiple tumors: a review of clinical trials.
@en
Evaluating temsirolimus activity in multiple tumors: a review of clinical trials.
@nl
type
label
Evaluating temsirolimus activity in multiple tumors: a review of clinical trials.
@en
Evaluating temsirolimus activity in multiple tumors: a review of clinical trials.
@nl
prefLabel
Evaluating temsirolimus activity in multiple tumors: a review of clinical trials.
@en
Evaluating temsirolimus activity in multiple tumors: a review of clinical trials.
@nl
P2093
P1433
P1476
Evaluating temsirolimus activity in multiple tumors: a review of clinical trials.
@en
P2093
Janet E Dancey
Joseph Purvis
Rafael Curiel
P304
P356
10.1053/J.SEMINONCOL.2009.10.010
P478
36 Suppl 3
P577
2009-12-01T00:00:00Z